OCUL vs. TAK

Last updated Jun 24, 2026

OCUL (Ocular Therapeutix, Inc.) and TAK (Takeda Pharmaceutical Company Limited) are both stocks. Both are in the Healthcare sector — OCUL in Biotechnology, TAK in Drug Manufacturers - Specialty & Generic. Over the past 10 years, OCUL returned 6.94%/yr vs 0.88%/yr for TAK. At a 0.15 correlation, their price movements are largely independent.

Performance

OCUL vs. TAK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ocular Therapeutix, Inc. (OCUL) and Takeda Pharmaceutical Company Limited (TAK). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, OCUL achieves a -16.68% return, which is significantly lower than TAK's 1.60% return. Over the past 10 years, OCUL has outperformed TAK with an annualized return of 6.94%, while TAK has yielded a comparatively lower 0.88% annualized return.

OCUL

• 1D: 1.45%
• 1M: 22.90%
• YTD: -16.68%
• 6M: -20.60%
• 1Y: 20.85%
• 3Y*: 27.59%
• 5Y*: -7.12%
• 10Y*: 6.94%

TAK

• 1D: 2.39%
• 1M: -2.52%
• YTD: 1.60%
• 6M: 2.46%
• 1Y: 10.03%
• 3Y*: 3.51%
• 5Y*: 2.25%
• 10Y*: 0.88%

*Multi-year figures are annualized to reflect compound growth (CAGR)

OCUL vs. TAK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
OCUL Ocular Therapeutix, Inc.	-16.68%	42.15%	91.48%	58.72%	-59.68%	-66.33%	424.05%	-0.75%	-10.56%	-46.83%
TAK Takeda Pharmaceutical Company Limited	1.60%	23.18%	-3.12%	-4.87%	20.08%	-23.45%	-5.18%	22.48%	-38.84%	41.29%

Correlation

The correlation between OCUL and TAK is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.16
Correlation (10Y) Calculated over the trailing 10-year period	0.16
Correlation (All Time) Calculated using the full available price history since Jul 25, 2014	0.15

The correlation between OCUL and TAK shifts across timeframes, from 0.06 (1 year) to 0.16 (10 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap OCUL : $2.27B TAK : $49.50B
EPS OCUL : -$1.45 TAK : ¥61.03
PS Ratio OCUL : 39.05 TAK : 1.78
PB Ratio OCUL : 3.90 TAK : 1.02
Total Revenue (TTM) OCUL : $52.04M TAK : ¥4.55T
Gross Profit (TTM) OCUL : $45.40M TAK : ¥2.66T
EBITDA (TTM) OCUL : -$283.03M TAK : ¥1.43T

Return for Risk

OCUL vs. TAK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OCUL

OCUL Risk / Return Rank: 53
OCUL Sharpe Ratio Rank: 54
OCUL Sortino Ratio Rank: 56
OCUL Omega Ratio Rank: 55
OCUL Calmar Ratio Rank: 52
OCUL Martin Ratio Rank: 50

TAK

TAK Risk / Return Rank: 54
TAK Sharpe Ratio Rank: 59
TAK Sortino Ratio Rank: 51
TAK Omega Ratio Rank: 50
TAK Calmar Ratio Rank: 54
TAK Martin Ratio Rank: 57

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

OCUL vs. TAK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ocular Therapeutix, Inc. (OCUL) and Takeda Pharmaceutical Company Limited (TAK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	OCUL	TAK	Difference
Sharpe ratio: Return per unit of total volatility	0.30	0.49	-0.19
Sortino ratio: Return per unit of downside risk	1.01	0.79	+0.22
Omega ratio: Gain probability vs. loss probability	1.12	1.10	+0.02
Calmar ratio: Return relative to maximum drawdown	0.37	0.50	-0.14
Martin ratio: Return relative to average drawdown	0.68	1.35	-0.66

OCUL vs. TAK - Sharpe Ratio Comparison

The current OCUL Sharpe Ratio is 0.30, which is lower than the TAK Sharpe Ratio of 0.49. The chart below compares the historical Sharpe Ratios of OCUL and TAK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

OCUL vs. TAK - Drawdown Comparison

The maximum OCUL drawdown since its inception was -95.19%, which is greater than TAK's maximum drawdown of -54.25%. Use the drawdown chart below to compare losses from any high point for OCUL and TAK.

Drawdown Indicators

	OCUL	TAK	Difference
Max Drawdown Largest peak-to-trough decline	-95.19%	-54.25%	-40.94%
Max Drawdown (1Y) Largest decline over 1 year	-57.29%	-20.05%	-37.24%
Max Drawdown (3Y) Largest decline over 3 years	-61.57%	-20.05%	-41.52%
Max Drawdown (5Y) Largest decline over 5 years	-85.50%	-24.50%	-61.00%
Max Drawdown (10Y) Largest decline over 10 years	-90.94%	-54.25%	-36.69%
Current Drawdown Current decline from peak	-76.62%	-30.30%	-46.32%
Average Drawdown Average peak-to-trough decline	-76.60%	-23.27%	-53.33%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.54%	7.47%	+23.07%

Volatility

OCUL vs. TAK - Volatility Comparison

Ocular Therapeutix, Inc. (OCUL) has a higher volatility of 17.41% compared to Takeda Pharmaceutical Company Limited (TAK) at 7.92%. This indicates that OCUL's price experiences larger fluctuations and is considered to be riskier than TAK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	OCUL	TAK	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.41%	7.92%	+9.49%
Volatility (6M) Calculated over the trailing 6-month period	54.37%	15.33%	+39.04%
Volatility (1Y) Calculated over the trailing 1-year period	70.06%	20.73%	+49.33%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	78.53%	19.58%	+58.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.83%	23.04%	+55.79%

Dividends

OCUL vs. TAK - Dividend Comparison

OCUL has not paid dividends to shareholders, while TAK's dividend yield for the trailing twelve months is around 2.03%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
OCUL Ocular Therapeutix, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
TAK Takeda Pharmaceutical Company Limited	2.03%	4.24%	4.67%	4.41%	4.23%	2.98%	2.30%	4.20%	4.77%	2.81%	3.99%	2.92%

Financials

Frequently Asked Questions

Can I hold both OCUL and TAK in my portfolio?

OCUL and TAK have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, OCUL or TAK?

OCUL has higher volatility (17.41%) compared to TAK (7.92%). In terms of maximum drawdown, OCUL dropped -95.19% vs TAK's -54.25%.

Which has better risk-adjusted returns?

TAK currently has the higher Sharpe Ratio (0.49 vs 0.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.